Strides Pharma Science

Bengaluru, India Founded: 1990 • Age: 36 yrs Listed Fortune India 500 · #320
Generic, semi-solid, and liquid dosage forms are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Strides Pharma Science

Strides Pharma Science is a publicly listed company based in Bengaluru (India) founded in 1990. Generic, semi-solid, and liquid dosage forms are manufactured. The company has 5,180 employees. Strides Pharma Science has completed 6 acquisitions, including Fairmed Healthcare, Generic Partners and Micelle BioPharma. Its website strides.com draws about 16 thousand monthly visits. Its Indian entity Strides Pharma Science Limited reported revenue of ₹5,010 Cr. Strides Pharma Science offers products and services including Finished Dosage Formulations and Soft Gelatin Capsules. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Strides Pharma Science was established in 1990 in Bengaluru, India. Operations are centered on the pharmaceutical sector, where generic medications along with semi-solid and liquid dosage forms are produced. The company maintains its headquarters in Bengaluru, supporting manufacturing activities that cater to global health needs through standard formulations. Focus remains on reliable production processes for essential drugs.

Strides Pharma Science is ranked #320 on the Fortune India 500 (2025).

Recognitions & Rankings of Strides Pharma Science

Fortune India 500 2025 edition
Rank#320
Total income
₹8,105 Cr
Profit
₹3,593 Cr
Last year #497
  • Headquarters Bengaluru, India
  • Employees 5,180
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website strides.com
  • Social LinkedIn X Facebook
  • Legal Name Strides Pharma Science Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹10,116 Cr

    STAR · NSE

  • Share Price
    ₹1,068.80

    -2.62% today

  • Revenue
    ₹4,859 Cr

    FY 2025-26 · +6.4% YoY

  • EBITDA
    ₹898 Cr

    Margin 18.5%

  • Net Profit
    ₹566 Cr

    FY 2025-26 · -83.9% YoY

  • P/E (TTM)
    17.3x

    P/B 3.2x

  • ROE
    20.3%

    ROCE 17.7%

  • Debt / Equity
    0.64

    Interest cover 25.6x

  • Investors
    Oman India Joint Investment Fund
  • Employee Count
    5,180
  • Investments & Acquisitions
    Fairmed Healthcare

    & 5 more

Products & Services of Strides Pharma Science

Strides Pharma Science offers a comprehensive portfolio of products and services, including Finished Dosage Formulations and Soft Gelatin Capsules.

Finished Dosage Formulations
Pharmaceutical Products

IP-led niche formulations are developed and manufactured for global distribution.

Soft Gelatin Capsules
Pharmaceutical Products

These capsules are produced as part of the company's manufacturing processes.

Funding Insights of Strides Pharma Science

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Strides Pharma Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2020Post-IPO––
Oman India Joint Investment Fund
Valuation history

1 investors in total: 1 institutional.

Investors in Strides Pharma Science

Strides Pharma Science has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Oman India Joint Investment Fund.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Oman India Joint Investment Fund
oijif.com
Premium access

Investor details for Strides Pharma Science

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Strides Pharma Science Limited (Strides Pharma Science)

Strides Pharma Science Limited is the primary company behind Strides Pharma Science. The board of Strides Pharma Science Limited currently have 9 directors; the longest-serving is Homi Rustam Khusrokhan, appointed in 2017. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Homi Rustam Khusrokhan
DIN 00005085
Director18 May 20179 yrs 5 moStrides Pharma Science Limited
Badree Komandur
DIN 07803242
Managing Director18 May 20179 yrs 5 moStrides Pharma Science Limited
Kausalya Santhanam
DIN 06999168
Director11 Dec 20196 yrs 10 moStrides Pharma Science Limited
Ameet Pratapsinh Hariani
DIN 00087866
Director01 Feb 20242 yrs 9 moStrides Pharma Science Limited
Subir Chakraborty
DIN 00130864
Director01 Jun 20242 yrs 5 moStrides Pharma Science Limited
Aditya Arun Kumar
DIN 06999081
Director01 Jun 20242 yrs 5 moStrides Pharma Science Limited
Mukta Malik Arora
DIN 07225715
Director01 Feb 20251 yr 8 moStrides Pharma Science Limited
Arun Kumar Pillai
DIN 00084845
Director05 Apr 20251 yr 6 moStrides Pharma Science Limited
Venkata Seetharama Raju Pakalapati
DIN 07500141
Whole-time director01 Jun 20265 moStrides Pharma Science Limited

People of Strides Pharma Science

16 people are tracked at Strides Pharma Science (6 in leadership, 10 in team); the tracked headcount is 5,180.

NameRoleGroup
Sohel Islam
Vice President UK OperationsLeadership
Sridhar S
Head Of OperationsLeadership
Arun Kumar
Founder and ChairmanLeadership
Pallavi Panchmatia
Head Of Corporate CommunicationsLeadership
Amol Mehta
Chief Executive Officer - B2c Other Reg MarketsLeadership
Sukumar Swamy
Head AdministrationLeadership
Halesh N R
Senior Group LeadTeam
Sathiyaraj G
Asst. Manager: Project ManagementTeam
Hari Haran
ExecutiveTeam
Prakash Babu N
Production Group LeadTeam
Parag Ramesh Mishra
Group LeaderTeam
Vasanth Kumar
Senior ExecutiveTeam
Manu Patil D.m Manu Patil D.m
ExecutiveTeam
Rajeev Ravindran
Sr. Executive - Graphic DesignerTeam
Asha Nalavade
Front Office ExecutiveTeam
Anbazhagan E
Production ManagerTeam
Premium access

Complete people profiles for Strides Pharma Science

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Strides Pharma Science

Strides Pharma Science is a publicly listed company on the NSE with ticker symbol STAR in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Aug 2013
  • Listed onNSE: STAR
  • Listed entityStrides Pharma Science Ltd
  • Exchange sectorHealth technology
  • ISININE939A01011
  • Share price₹1,081.20 (-1.31% on the day) · 2026-10-14
  • Market capitalisation₹10,121 Cr
  • Price to earnings16.2
  • EPS (diluted, trailing year)₹66.55
  • Dividend yield0.46%
  • Volume (last session)73,412

Financials of Strides Pharma Science

Exchange-reported figures of Strides Pharma Science Limited, the listed company behind Strides Pharma Science (NSE: STAR).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,859 Cr
+6.4% YoY
EBITDA
₹898 Cr
+18.2% YoY
Profit After Tax
₹566 Cr
-83.9% YoY
Net Worth
₹3,108 Cr
+21.8% YoY
Total Assets
₹5,065 Cr
+10.2% YoY
Total Debt
₹1,758 Cr
-6.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Profit before tax6693,675(65.21)(268)(653)28941.92
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Balance sheet
Total assets5,0654,5954,6945,2905,5315,4864,963
Net worth3,1082,5522,1262,2122,3592,7772,527
Total debt1,7581,8802,5173,0303,0252,3482,235
Cash & bank213137191316187180237
Net working capital1,8721,6951,7581,8881,9531,2351,085
Cash flow
Cash from operations70368470144.41(258)481205
Cash from investing(173)(90.25)(150)302(119)(522)1,321
Cash from financing(453)(643)(693)(214)421(15.80)(1,709)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%---
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Profit before tax2032,90545.88(64.75)21.50112136
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
Balance sheet
Total assets4,5484,4485,2634,9034,7254,3774,085
Net worth3,2843,1933,5283,4553,4073,2483,159
Total debt1,1841,2021,6881,4141,284917902
Cash & bank40.6830.5011585.5814.4573.04110
Net working capital1,5261,5621,7721,4091,266899804
Cash flow
Cash from operations278421(14.01)242(283)283138
Cash from investing(69.07)(138)(68.69)(183)18.78(276)62.83
Cash from financing(199)(370)93.3410.82251(48.64)(204)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%---
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 01 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%---
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
Other income1513,35689.85247188203157
Total expenses3,9603,8053,5513,6993,5012,8732,538
Employee cost929863737732647550443
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Depreciation202192214243233206174
Interest179249280261177150156
Profit before tax6693,675(65.21)(268)(653)28941.92
Tax94.1777.5229.11(55.30)(178)31.6511.33
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,0152,4602,0342,1052,2692,6872,438
Shareholders' funds (net worth)3,1082,5522,1262,2122,3592,7772,527
Minority interest41.7734.63(53.86)(39.38)24.0937.3467.24
Secured loans1,4991,6502,2412,5682,1092,0331,955
Unsecured loans259229276461916316279
Total debt1,7581,8802,5173,0303,0252,3482,235
Total liabilities5,0654,5954,6945,2905,5315,4864,963
Assets
Gross block3,3042,9112,8873,3393,2462,9382,631
Net block2,1011,8991,8652,3112,3472,2192,099
Capital work in progress447207162151291447413
Investments291409303490540697549
Inventories1,6351,2781,1261,1471,1741,201783
Sundry debtors1,2891,2031,1421,2991,2071,107932
Cash & bank balances213137191316187180237
Loans & advances476412404431793230302
Total current assets3,6133,0292,8633,1933,3622,7182,253
Total current liabilities1,7421,3351,1061,3041,4091,4831,168
Net working capital1,8721,6951,7581,8881,9531,2351,085
Total assets5,0654,5954,6945,2905,5315,4864,963
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash113161304171126182366
Net cash from operating activities70368470144.41(258)481205
Net cash from investing activities(173)(90.25)(150)302(119)(522)1,321
Net cash from financing activities(453)(643)(693)(214)421(15.80)(1,709)
Net change in cash76.13(48.46)(142)13344.90(56.40)(184)
Closing cash213137191316187180237
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
EBITDA growth+18.2%+124.5%+3424.8%+97.6%-197.3%+107.0%-
PBT growth-81.8%+9998.0%+75.6%+59.0%-+590.3%-86.2%
Net income growth-83.9%+2269.5%+178.3%+16.8%-200.6%+263.1%-
Revenue CAGR (3Y)+9.6%+14.1%+5.5%+10.3%+12.1%+5.2%-0.0%
EBITDA CAGR (3Y)---8.5%--+8.1%-23.4%
Profitability & leverage
Net income margin+11.8%+78.8%-2.4%-5.8%-15.5%+7.8%+1.1%
Return on capital employed+17.7%+14.3%0.0%0.0%-4.4%+7.3%+5.1%
Return on net worth+20.3%+150.7%0.0%0.0%-9.4%+8.1%+2.2%
Debt / equity0.640.941.281.321.050.861.05
Long-term debt / equity0.220.290.480.520.410.370.51
Interest cover25.6543.80223.89-103.04-26.6363.46387.65
Efficiency & per share
Fixed asset turnover1.561.571.251.120.991.190.81
Inventory turnover3.343.803.423.182.593.343.32
Debtors turnover3.903.893.192.942.653.252.87
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)337.14276.88231.28243.09262.70309.62282.19
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%---
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
Other income1232,87312884.0712311793.07
Total expenses1,8951,8771,7211,7711,9021,6981,487
Employee cost382378349267272273230
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Depreciation91.2484.6187.4193.6210499.3494.24
Interest11414613913974.2465.3466.84
Profit before tax2032,90545.88(64.75)21.50112136
Tax19.4718.931.34(69.44)(159)33.3916.17
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,1913,1013,4363,3483,3163,1583,069
Shareholders' funds (net worth)3,2843,1933,5283,4553,4073,2483,159
Secured loans9951,0241,5271,2541,122792846
Unsecured loans19017816116016212555.18
Total debt1,1841,2021,6881,4141,284917902
Total liabilities4,5484,4485,2634,9034,7254,3774,085
Assets
Gross block1,5801,4931,4601,1961,1421,0991,020
Net block785767747597617644651
Capital work in progress18110610755.3855.72111112
Investments1,8681,8482,3642,4922,4002,3952,171
Inventories580432498491513689463
Sundry debtors1,5211,4531,5651,3081,296822656
Cash & bank balances40.6830.5011585.5814.4573.04110
Loans & advances231230233242151160167
Total current assets2,3742,1462,4112,1261,9751,7441,396
Total current liabilities847583639717709845592
Net working capital1,5261,5621,7721,4091,266899804
Total assets4,5484,4485,2634,9034,7254,3774,085
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.3392.7582.1112.1225.3066.8269.91
Net cash from operating activities278421(14.01)242(283)283138
Net cash from investing activities(69.07)(138)(68.69)(183)18.78(276)62.83
Net cash from financing activities(199)(370)93.3410.82251(48.64)(204)
Net change in cash9.84(86.42)10.6569.98(13.18)(41.52)(3.09)
Closing cash40.6830.5011585.5814.4573.04110
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
EBITDA growth+8.6%+80.8%+73.9%+9.0%-51.9%-22.1%-
PBT growth-93.0%+6232.0%+9998.0%--80.7%-18.2%+25.2%
Net income growth-97.5%+5664.6%+138.3%-88.1%+134.7%-35.8%-
Revenue CAGR (3Y)+5.5%+2.6%+0.2%+3.1%+8.8%+8.1%+7.0%
EBITDA CAGR (3Y)+50.6%+50.7%-3.0%-25.8%-16.5%-1.0%+23.5%
Profitability & leverage
Net income margin+8.4%+134.9%+2.4%+0.3%+9.1%+4.2%+7.1%
Return on capital employed+4.8%+4.6%+2.4%+1.9%+1.9%+4.2%+5.0%
Return on net worth+2.3%+85.9%+1.4%+0.6%+5.3%+2.4%+3.8%
Debt / equity0.370.430.440.390.330.280.27
Long-term debt / equity0.050.060.080.070.050.030.01
Interest cover58.7082.06241.48-1,367.65-267.53109.1260.64
Efficiency & per share
Fixed asset turnover1.421.451.411.591.771.751.82
Inventory turnover4.314.603.773.693.293.233.61
Debtors turnover1.471.421.301.421.872.512.73
EPS (₹)19.92313.164.850.5220.078.7213.43
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)356.23346.42383.84380.71379.36362.18352.68

Investments & Acquisitions by Strides Pharma Science

Strides Pharma Science has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Fairmed Healthcare, Generic Partners and Micelle BioPharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Stelis Biopharma
Offers contract development and manufacturing for drug products globally.
stelis.comBengaluru, India2013Sep 2019••••
Fairmed Healthcare
Manufacturer of generic medicines
fair-med.comZug, Switzerland2012Sep 2019$2.21M
Micelle BioPharma
Developer of orphan drugs for treating sickle cell based diseases
micellebiopharma.comRiviera Beach, United States2018Aug 2019$500,000
Vensun Pharmaceuticals
Generic prescription pharmaceuticals are developed and distributed in various forms.
vensunrx.comYardley, United States2011Jan 2019$18M
Pharmapar
Generic drugs are distributed in Canada by Pharmapar.
pharmapar.caVarennes, Canada1998Jan 2019$3M
Generic Partners
Consulting services in strategy, innovation, operational experience, and marketing.
genericpartners.com.auPune, India2009Feb 2016$10.59M
Premium access

Complete acquisition details for Strides Pharma Science

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Strides Pharma Science

9 dated milestones of Strides Pharma Science across 30 years, from founding to its latest funding, stage changes and deals.

  1. Founded Strides Pharma Science is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Generic Partners.
  4. Acquisition Acquires Pharmapar.
  5. Acquisition Acquires Vensun Pharmaceuticals.
  6. Acquisition Acquires Micelle BioPharma.
  7. Acquisition Acquires Fairmed Healthcare.
  8. Acquisition Acquires Stelis Biopharma.
  9. Funding First funding round.

Web traffic of Strides Pharma Science

The website of Strides Pharma Science (strides.com) receives about 15.7K visits a month and ranks #1,592,167 among all websites worldwide, #2,143 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    15.7K

    ▼ 8% vs previous month

  • Unique visitors
    8.5K

    per month

  • Global rank
    #1,592,167

    among all websites

  • Category rank
    #2,143

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Strides Pharma Science. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Bal Pharma
balpharma.com
100%
3K#7,146,280View details
Micro Labs
microlabsltd.com
98%
#1,920,866View details
Medreich
medreich.com
96%
1.9K#7,047,446View details
kaplindia.com
kaplindia.com
93%
#6,271,095–
Global Calcium
globalcalcium.com
88%
#2,271,380View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 10 similar websites and full traffic analytics for Strides Pharma Science

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Strides Pharma Science (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Mankind Pharma
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations
1991Delhi, Delhi, IndiaUSD 367.2 MUSD 1.52 B21,320
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Strides Pharma Science

STAR: Q2 REVENUE 14.3B RUPEES VS 12.2B (YOY)
Exchange Update • 3 days ago
STAR: Q2 CONS NET PROFIT 1.31B RUPEES VS 1.3B (YOY)
Exchange Update • 3 days ago
STAR: Q2 EBITDA 2.5B RUPEES VS 2.32B (YOY); Q2 EBITDA MARGIN 17.54% VS 18.97% (YOY)
Exchange Update • 3 days ago
Ascent Capital-backed Pivot Path eyes scale after Strides demerger
VCCircle • 1 month ago
18 stocks including BSE, LIC, HDFC Bank, Aditya Infotech, Ramco Systems, Titagarh Rail, Gravita, Strides, Dr Lal Path in focus today - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Reuters • 2 months ago
Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Reuters • 2 months ago
Q1 results 2026: ITC to Maruti Suzuki, Sun Pharma, among companies to declare Q1 earnings today; full list here
Mint • 3 months ago
STAR: Revenue up 13% YoY, Ex-US markets strong, EBITDA rises, net debt down, outlook positive
Quartr • 3 months ago
Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Reuters • 3 months ago
Premium access

Complete news archive for Strides Pharma Science

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Strides Pharma Science

Strides Pharma Science was founded in 1990 and raised its 1st funding round 30 years after it was founded.

Strides Pharma Science is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Strides Pharma Science has 5,180 employees.

The primary company behind Strides Pharma Science, Strides Pharma Science Limited, reported revenue of ₹5,010 Cr for FY 2026, up 6% year on year.

Strides Pharma Science was established in 1990 in Bengaluru, India. Operations are centered on the pharmaceutical sector, where generic medications along with semi-solid and liquid dosage forms are produced. The company maintains its headquarters in Bengaluru, supporting manufacturing activities that cater to global health needs through standard formulations. Focus remains on reliable production processes for essential drugs.

Strides Pharma Science offers Finished Dosage Formulations and Soft Gelatin Capsules.

Yes, Strides Pharma Science is publicly traded on NSE under the ticker symbol STAR.

Strides Pharma Science has made 6 acquisitions, including Fairmed Healthcare, Generic Partners, and Micelle BioPharma.

Strides Pharma Science has 1 investor. Key investors include Oman India Joint Investment Fund.

Strides Pharma Science operates through Strides Pharma Science Limited.

The legal entities of Strides Pharma Science currently have 11 directors, including Arun Kumar Pillai, Kausalya Santhanam, Manjula Ramamurthy and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available